Alpha 2.0
Login Register
» Authors » Pornjarim Nilyanimit

Pornjarim Nilyanimit

Explore the profile of Pornjarim Nilyanimit including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 299
Followers 0
Related Specialties
Science
Infectious Diseases
Microbiology
Top 10 Co-Authors
Yong Poovorawan
Nasamon Wanlapakorn
Nungruthai Suntronwong
Preeyaporn Vichaiwattana
Jira Chansaenroj
Sitthichai Kanokudom
Suvichada Assawakosri
Donchida Srimuan
Thanunrat Thongmee
Natthinee Sudhinaraset
Published In
Vaccines (Basel)
Sci Rep
PLoS One
Asian Pac J Cancer Prev
Int J Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
11.
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
Yorsaeng R, Atsawawaranunt K, Suntronwong N, Kanokudom S, Chansaenroj J, Assawakosri S, et al.
Vaccines (Basel) . 2023 Jul; 11(7). PMID: 37515001
The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of vaccination. In Thailand, more than 77% and...
12.
An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA
Hansoongnern P, Pratedrat P, Nilyanimit P, Wasitthankasem R, Posuwan N, Wanlapakorn N, et al.
PLoS One . 2023 Jun; 18(6):e0287694. PMID: 37384719
Hepatitis C virus (HCV) is a viral pathogen that causes chronic hepatitis, which can lead to cirrhosis and hepatocellular carcinoma. Detection of HCV RNA is the standard method used to...
13.
Development of a simplified and cost-effective sample preparation method for genotyping of human papillomavirus by next-generation sequencing
Jitvaropas R, Thongpoom U, Sawaswong V, Khongnomnan K, Poomipak W, Praianantathavorn K, et al.
Arch Virol . 2023 Jun; 168(7):185. PMID: 37340138
High-risk human papillomavirus (HPV) infection is the most common cause of cervical cancer, but low-risk HPV strains can sometimes also be involved. Although HPV genotyping techniques used in clinical diagnosis...
14.
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years
Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, et al.
J Med Virol . 2023 May; 95(5):e28758. PMID: 37212319
To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children...
15.
Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policy
Vongpunsawad S, Rhee C, Nilyanimit P, Poudyal N, Jiamsiri S, Ahn H, et al.
IJID Reg . 2023 Apr; 7:110-115. PMID: 37009571
Objective: The aim of this study was to determine the prevalence of high-risk (HR) and vaccine-type human papillomavirus (HPV) infection among Thai schoolgirls who were not included in the national...
16.
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al.
Vaccines (Basel) . 2023 Mar; 11(3). PMID: 36992154
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg...
17.
Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand
Pratedrat P, Nilyanimit P, Wasitthankasem R, Posuwan N, Auphimai C, Hansoongnern P, et al.
PLoS One . 2023 Jan; 18(1):e0268728. PMID: 36656832
The World Health Organization envisions the elimination of viral hepatitis by 2030 through reducing prevalence and transmission, increasing diagnostic screening, and expanding treatment coverage. Efforts to micro-eliminate hepatitis in Phetchabun...
18.
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax) after homologous and heterologous two-dose regimens
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al.
Int J Infect Dis . 2022 Nov; 126:64-72. PMID: 36427701
Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: A...
19.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.
Vaccine . 2022 Aug; 40(39):5657-5663. PMID: 36031500
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The...
20.
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, et al.
J Med Virol . 2022 Aug; 94(12):5713-5722. PMID: 35924475
The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion even in individuals with complete vaccination, because it harbors mutations. Here we examine the capability of...